Protagonist Therapeutics (PTGX) Cash from Investing Activities (2015 - 2026)

Protagonist Therapeutics has reported Cash from Investing Activities for 12 years, with the latest figure at $90.9 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 196.28% year-over-year to $90.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136.0 million (up 133.99% YoY) and the FY2025 annual result came in at -$49.3 million, up 83.53% from the prior year.
• Cash from Investing Activities grew to $90.9 million in Q1 2026 per PTGX's latest filing, from $48.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $90.9 million in Q1 2026 and troughed at -$208.7 million in Q3 2024.
• A 5-year average of -$12.1 million and a median of $3.9 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities plunged 1657.48% in 2023, then soared 659.48% in 2025.
• Over 5 years, Cash from Investing Activities stood at $3.9 million in 2022, then slumped by 1657.48% to -$61.3 million in 2023, then soared by 85.76% to -$8.7 million in 2024, then jumped by 659.48% to $48.8 million in 2025, then soared by 86.2% to $90.9 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $90.9 million, $48.8 million, and -$58.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.